Investigating a new drug to treat Acute Myeloid Leukemia (AML)

What we are studying

The purpose of this study is to find out the affects (good and bad) that administering a Vincristine Sulfate Liposome injection (VSLI) has on your condition. VSLI is approved by the United States Food and Drug Administration (FDA) for the treatment of adults with Acute Lymphoblastic Leukemia (ALL), but has not been approved for individuals with AML. VSLI works by slowing or stopping the growth of cancer cells in the body.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with relapsed or refractory Acute Myeloid Leukemia (AML)
  • Not pregnant or nursing

What is involved

  • Visits to the clinic for treatment with Vincristine Sulfate Liposome injection
  • Follow-Up visits to the clinic to see how you are doing

Compensation

None

Contact Information

Study Coordinator
Teresa Brady
Email
tbrady@wakehealth.edu
Phone
336-716-4703

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.